Europe Testosterone Replacement Therapy Market

Europe Testosterone Replacement Therapy Market Size (2024 to 2029)

The size of the testosterone replacement therapy market in Europe is predicted to be worth USD 0.86 bn by 2029 from USD 0.69 bn in 2024, growing at a CAGR of 4.41% from 2024 to 2029.

The European testosterone replacement therapy market was the second largest by share in the global market in 2023.

The growing aging population and Y-O-Y growth in hypogonadism incidence are the factors impelling market growth. Reducing the testosterone levels in the elderly male population aged between 40 to 79 years is happening at a high rate, and increasing awareness for testosterone replacement therapies and the innovations of TRT technologies such as spray-on and unchanged testosterone are also contributing to the European TRT market growth.

Additionally, the presence of disease conditions and heredity with reproductive diseases following in the family, and the growing peril of fewer testosterone levels such as hormonal imbalance are anticipated to drive growth for the European TRT market during the forecast period. The rising incidence of chronic diseases and an increasing geriatric population among all the European countries are further favoring the market to grow higher. Also, high investments in the development of new technologies are adding fuel to the growth of the market.

The European testosterone replacement therapy market growth is slightly restrained by factors such as side effects associated with therapies like metabolic and heart-related ailments. Lack of awareness among people, especially males, regarding testosterone replacement therapy, is a significant drawback to the market.

This research report on the Europe TRT market has been segmented & sub-segmented into the following categories

Europe Testosterone Replacement Therapy Market - By Product Type

• Patches    
• Injections
• Adhesives               
• Implants  
• Oral        

Europe Testosterone Replacement Therapy Market - By Active Ingredient

• Testosterone Undecanoate            
• Testosterone Enanthate   
• Testosterone Cypionate   
• Methyl Testosterone        

Europe Testosterone Replacement Therapy Market - By Country

• United Kingdom
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Rest of Europe

The European region accounted for the second-largest share of testosterone replacement therapy in the world.

Factors such as the growing geriatric population and rising incidence of hypogonadism are expected to propel the market growth in this region.

Germany and the UK are two promising nations in the European TRT market. They are predicted to rise at a robust CAGR during the forecast period due to their rapidly growing aging population. Moreover, the increasing stipulation for testosterone replacement therapy is supporting the market in these countries.

Other European countries such as Italy, France, and Spain are expected to grow at a steady CAGR in the forthcoming years throughout the period. Growing male infertility issues due to lifestyle changes and increasing stress is also an attribute for increasing enormously.

KEY MARKET PLAYERS

Companies playing a notable role in the European testosterone replacement therapy market analyzed in this report are Pfizer Inc., Allergan Plc., AbbVie Inc., Bayer AG., Eli Lilly and Company, Endo Pharmaceuticals, Kyowa Kirin International Plc., Novartis AG. and Mylan N.V. among others.